Representative Matters
REFERENZMANDATE
代表事项
Patent Counseling
- Pre-ANDA strategy for extending patent term and exclusivities relating to a marketed small molecule therapeutic
- Aptinyx on patent matters relating to NMDA small molecule modulators, including patent matters leading to its $65 million Series A financing, and its recent IPO
- Assembly Biosciences on patent matters relating to its HBV and microbiome programs and its $69 million public follow-on offering
- Ascentage Pharma on patent matters relating U.S. patent strategy and its $53 million initial public offering on the Hong Kong Stock Exchange
- BridgeBio Pharma and subsidiary companies on patent portfolio strategy for orphan genetic diseases leading to its NASDAQ public offering
- Nogra Pharma Ltd. (Ireland) on patent portfolio strategy and patent matters relating to small molecule therapeutics including PPARg modulators; IL-34 technology; and SMAD7 antisense therapy
- AMAG Pharmaceuticals on patent matters relating to its marketed products, including Feraheme®, and its $201 million follow-on and $225 convertible note offerings
- Naurex Inc. on patent portfolio development and patent matters relating to its NMDA small molecule and peptidyl programs and in connection with its $560 million merger with Allergan PLC
- Aegerion Pharmaceuticals on patent matters relating to the approved small molecule lomitapide and BLA approved product metreleptin; including representing the licensor/patent owner in an inter partes review involving patents directed to a novel dosing regimen for lomitapide, with Final Written Decisions upholding the validity of the patents (Coalition for Affordable Drugs VIII, LLC v. The Trustees of the University of Pennsylvania)
- Neuroderm Ltd. (Israel) on patent matters relating to its CNS small molecule therapeutics, its U.S. IPO and later acquisition by Mitsubishi Tanabe Pharma Company for an equity value of approximately $1.1 billion
- Proteostasis Therapeutics on patent prosecution matters and strategy relating to its cystic fibrosis transmembrane regulator small molecule program, including patent matters leading to its $50 million initial public offering and $65 million and $40 million follow-on public offerings
- Full life cycle patent strategy on behalf of a pharmaceutical company with a recently approved orphan drug
- Early stage platform and discovery stage patent strategies for several pharmaceutical and biological therapeutic companies
- Preparation of the published patent application that includes the CAS Registry 100 millionth substance, (4S)-6-(4-chlorophenyl)-N-ethyl-8-[2-[[4[hydroxydimethylsilyl)-methyl]benzoyl]amino]ethoxy]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide
Professional Activities
Dr. Kavanaugh is a member of the American Intellectual Property Law Association, the Boston Patent Law Association and the American Chemical Society.
